A$800,000 Grant For Commercialisation


Cancer Diagnostics has been awarded a Federal Government grant to commercialise its innovative technology for use in a new, simple and cost-effective urine test for bladder cancer.

The Commercialisation grant will enable Sienna to advance its clinical evaluation programmes, progress its initial licensing agreements in the USA (the world’s largest market) and recruit new senior staff to drive its global product launch.

Sienna’s Managing Director and CEO Dr Kerry Hegarty commented: “We are extremely pleased to receive this funding from Commercialisation Australia. Without question, this unique source of funding and access to commercial expertise will be directly responsible for enabling us to fast-track our revenue stream and future product development on a global scale.”

$800,000 Commercialisation Australia grant awarded to Sienna for development of telomerase based IVD


No Very

Captcha Image

Sign up for updates